US20050058706A1 - Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol - Google Patents

Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol Download PDF

Info

Publication number
US20050058706A1
US20050058706A1 US10/831,368 US83136804A US2005058706A1 US 20050058706 A1 US20050058706 A1 US 20050058706A1 US 83136804 A US83136804 A US 83136804A US 2005058706 A1 US2005058706 A1 US 2005058706A1
Authority
US
United States
Prior art keywords
weight
ethyl
methyl
dimethylamino
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/831,368
Inventor
Johannes Bartholomaeus
Iris Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grunenthal GmbH
Original Assignee
Grunenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to DE2001152469 priority Critical patent/DE10152469A1/en
Priority to DE10152469.2 priority
Priority to DE2002148309 priority patent/DE10248309A1/en
Priority to DE10248309.4 priority
Priority to PCT/EP2002/011809 priority patent/WO2003035053A1/en
Application filed by Grunenthal GmbH filed Critical Grunenthal GmbH
Assigned to GRUENENTHAL GMBH reassignment GRUENENTHAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARTHOLOMAEUS, JOHANNES, ZIEGLER, IRIS
Publication of US20050058706A1 publication Critical patent/US20050058706A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050058706(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

A pharmaceutical formulation for delayed release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of international patent application no. PCT/EP02/11809, filed Oct. 22, 2002, designating the United States of America, and published in German as WO 03/035053, the entire disclosure of which is incorporated herein by reference. Priority is claimed based on Federal Republic of Germany patent application nos. DE 101 52 469.2, filed Oct. 24, 2001, and DE 102 48 309.4, filed Oct. 16, 2002.
  • BACKGROUND OF THE INVENTION
  • The present invention relates to a slow-release pharmaceutical formulation, containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof in a matrix.
  • 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol is known from European patent no. EP 693,475 as an analgesic pharmaceutical composition and can be administered orally. Conventional formulations for oral administration of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol lead to rapid release of the active ingredient in the gastrointestinal tract, so its analgesic action begins rapidly. At the same time, a rapid reduction in the action is observed. Therefore, the treatment of pronounced chronic pain with 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol formerly required administration of the pharmaceutical composition at relatively short intervals, for example four to eight times daily, to ensure an adequately high concentration of active ingredient in the patient's blood plasma. However, the need for frequent dosing easily leads to errors in administration and to undesirable variations in concentration in the plasma which are detrimental to patient compliance and the therapeutic benefit, particularly when treating chronically painful conditions. It is therefore desirable to have a slow release pharmaceutical composition (retard formulation) for oral administration of the active ingredient, 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol.
  • In the prior art, retard formulations are generally known for a large number of different active ingredients. Conventional forms of retardation include coating retardation and matrix retardation.
  • In coating retardation as described, for example, in published German patent application no. DE 36 25 458, the nucleus of a pharmaceutical composition containing an active ingredient is provided with a coating which consists of one or more hydrophilic and/or hydrophobic polymers and slows down release of the active ingredient.
  • In matrix retardation, the active ingredient is contained in a matrix which is formed from one or more excipients and controls release of the active ingredient. Published German patent application no. DE 33 09 516, for example, accordingly discloses a process for producing matrix formulations with hydroxypropylmethyl cellulose (HPMC) as excipient and slow release, in part, of the active ingredient, the excipient making up not more than one third of the weight of the formulation and consisting of at least one hydroxypropylmethyl cellulose having a methoxy content of 16 to 24% by weight, a hydroxypropyl content of 4 to 32% by weight and a numerically averaged molecular weight of at least 50,000. The formulations disclosed in DE 33 09 516 A1 contain HPMCs having viscosities (in a 2% by weight aqueous solution at 20° C.) between 15 and 30,000 cPs (15 to 30,000 mPa·s). Release behavior which is independent of the pH of the dissolution medium is not disclosed in DE 33 09 516 A1.
  • SUMMARY OF THE INVENTION
  • Accordingly, it is an object of the present invention to provide a pharmaceutical formulation which achieves slow release of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol.
  • This object and other objects are achieved in accordance with the present invention by a slow-release pharmaceutical formulation containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof in a matrix with slow release of active ingredient, in which the matrix contains 1 to 80% by weight, preferably 5 to 80% by weight, of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix forming agents and has the following release rate in vitro, measured by the Ph. Eur. Paddle Method at 75 rpm in a buffer (to Ph. Eur.) at a pH of 6.8 at 37° C. and detected using a UV spectrometer:
      • 3 to 35% by weight (based on 100% by weight active ingredient) of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours;
      • 5 to 50% by weight of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour;
      • 10 to 75% by weight of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours;
      • 15 to 82% by weight of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours;
      • 30 to 97% by weight of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours;
      • more than 50% by weight of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours;
      • more than 70% by weight of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and
      • more than 80% by weight of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.
        It has surprisingly been found that the formulation according to the invention releases the active ingredient, 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, slowly when administered orally and is therefore suitable for administration at intervals of at least 12 hours. The formulation according to the invention therefore enables pain therapy, during which the analgesic, 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, only has to be administered once daily, for example at 24 hour intervals, or twice daily, preferably at 12 hourly intervals, in order to ensure an adequate concentration of the active ingredient in the plasma. A corresponding duration of efficacy and the maintenance of an adequate level in the blood plasma are demonstrated by simulation studies and experimental investigations.
  • It is particularly surprising that the formulation according to the invention not only ensures long-lasting therapeutic efficacy over a relatively long period (at least 12 hours) due to the slow release of the active ingredient, but at the same time allows the active ingredient to start flowing rapidly in the plasma when the pharmaceutical composition is first administered, leading to a rapid onset of pain relief in the patient. Therefore, the pain suffered by a patient can rapidly be alleviated when the formulation according to the invention is administered without the analgesic action quickly fading again. The formulation according to the invention therefore combines properties of a formulation with immediate release of active ingredient—rapid pain relief due to adequately high concentration of active ingredient just after administration of the pharmaceutical composition—with properties of a formulation having slow release—long-lasting analgesic action due to maintenance of an adequately high level of active ingredient over a prolonged time. By taking the analgesic in the formulation according to the invention, the patient can effectively combat his pain acutely and, at the same time, treat it effectively over a prolonged period without further measures and merely by regular administration at 12 (or 24) hourly intervals.
  • The active ingredient of the formulation according to the invention is contained in a slow release matrix. It is also conceivable, however, that the active ingredient be contained in a matrix with conventional release behavior and the slow release be achieved by a retarding coating.
  • In a further possibility the slow release behavior is achieved by an osmotically driven release system.
  • If the formulation according to the invention contains a slow release matrix, the matrix contains 1 to 80% by weight of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix forming agents, for example rubbers, cellulose ethers, cellulose esters, acrylic resins, materials derived from proteins, fats, waxes, fatty alcohols or fatty acid esters. When using hydrophilic polymers as matrix forming agents, it is preferable for the matrix to comprise 5 to 80% by weight matrix forming agents.
  • The present invention also relates to a pharmaceutical formulation which contains 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof in a matrix with slow release of active ingredient, in which the matrix contains 1 to 80% by weight, in particular 5 to 80 by weight, of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix forming agents and which comprise cellulose ethers and/or cellulose esters having a viscosity (determined using a Pharm. Eu. capillary viscosimeter) of 3,000 to 150,000 mPa·s in a 2% by weight aqueous solution at 20° C. as pharmaceutically acceptable matrix forming agents. These compositions have the above-mentioned release profile according to the invention.
  • Preferred pharmaceutically acceptable matrix forming agents include cellulose ethers and/or cellulose esters having a viscosity between 10,000, in particular 50,000 mPa·s, and 150,000 mPa·s in a 2% by weight aqueous solution at 20° C.
  • Particularly suitable pharmaceutically acceptable matrix forming agents may be selected from the group consisting of hydroxypropylmethyl celluloses (HPMC), hydroxyethyl celluloses, hydroxypropyl celluloses (HPC), methyl celluloses, ethyl celluloses and carboxymethyl celluloses and are selected, in particular, from the group consisting of HPMCs, hydroxyethyl celluloses and HPCs. HPMCs having a viscosity of approx. 100,000 mPa·s, measured in a 2% by weight aqueous solution at 20° C. are most preferred.
  • The active ingredient, 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, exists as such, i.e. as a free base, but also in the form of pharmaceutically acceptable salts, for example as a hydrochloride. Preparation of the free base is known from published European patent application no. EP 693,475. Where EP 693,475 does not also disclose the preparation of pharmaceutically acceptable salts such as hydrochloride, these may be obtained from the free base by processes generally known in the art.
  • 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol has two asymmetric centers, so the compound can exist in the form of four different stereoisomers. In the formulation according to the invention 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol can exist as a mixture of all four diastereomers in any ratio, but also as a mixture of two or three of the four stereoisomers or in pure stereoisomer form. Preferred stereoisomers include (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, which, in the formulation according to the invention, can exist as a mixture, in particular as a 1:1 mixture (racemate) or particularly preferably in pure isomer form. For the purposes of the present invention, therefore, the term “active ingredient” denotes 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol as a mixture of various stereoisomers thereof or as one pure stereoisomer thereof as a free base or in the form of a pharmaceutically acceptable salt respectively.
  • In the pharmaceutical compositions according to the invention, the slow release active ingredient content is preferably between 0.5 and 85% by weight and the content of pharmaceutically acceptable matrix forming agents between 8 and 40% by weight. Particularly preferred pharmaceutical compositions have a slow release active ingredient content between 3 and 70% by weight, in particular between 8 and 66% by weight, and a content of pharmaceutically acceptable matrix forming agents between 10 and 35% by weight, in particular between 10 and 30% by weight. If enantiomerically pure (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol (or a mixture of the (+) and (−) enantiomers with a large excess of the (+) enantiomer) is used as active ingredient, it is particularly preferred if the active ingredient content lies at the lower limit, i.e. between 0.5 and 25% by weight (based on the total weight). If enantiomerically pure (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol (or a mixture of the (+) and (−) enantiomers with a large excess of the (−) enantiomer) is used as active ingredient, it is particularly preferred if the active ingredient content lies between 16 and 66% by weight.
  • Further components of the matrix of the formulation according to the invention may optionally include digestible long-chain (i.e. with 8 to 50 carbon atoms, preferably 12 to 50 carbon atoms) unsubstituted or substituted hydrocarbons such as fatty alcohols, fatty acid glyceryl esters, mineral and vegetable oils as well as waxes. Hydrocarbons having a melting point between 25° and 90° C. are preferred. Fatty alcohols are particularly preferred and lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol and cetylstearyl alcohol are more particularly preferred. Their content in the matrix may be 0 to 60% by weight. The matrix can alternatively or additionally contain polyethylene glycols in a content of 0 to 60% by weight.
  • The pharmaceutical formulations according to the invention can also contain, as further components, pharmaceutically acceptable auxiliaries such as fillers, for example lactose, microcrystalline cellulose (MCC) or calcium hydrogen phosphate as well as glidants, lubricants and flow regulators such as talcum, magnesium stearate, stearic acid and/or highly dispersed silicon dioxide, of which the total content in the tablet may be between 0 and 80% by weight, preferably between 5 and 65% by weight.
  • The release rate of an active ingredient from an administrable form frequently depends on the pH of the release medium. This can vary in a pH range from less than 1 to about 8 as the pharmaceutical composition passes through the gastrointestinal tract. These variations also can vary from one person to another. One and the same person can also have a different pH/time profile during passage through the gastrointestinal tract from one administration to another. Thus, if the release rate of the active ingredient from the pharmaceutical composition is dependent on the pH, this can lead to different release rates in vivo and therefore different biocompatibility.
  • Surprisingly, however, the release profiles of the active ingredient (either in the form of the base or of a pharmaceutically acceptable salt thereof) from a pharmaceutical formulation according to the invention are independent of the pH which can occur physiologically during passage through the gastrointestinal tract. The release profiles with an ambient pH of 1.2, 4.0 and 6.8 are identical to one another and also in comparison to the release during a pH/time profile from pH 1.2 via pH 2.3 and pH 6.8 to pH 7.2.
  • It has been found that it is immaterial for achieving the slow release of active ingredient from the formulation according to the invention, which preferably exists in tablet form, whether a water-soluble filler, for example lactose, an insoluble filler which does not swell in an aqueous medium, for example calcium hydrogen phosphate, or an insoluble filler which swells in an aqueous medium, for example microcrystalline cellulose, is used as filler with otherwise unchanged values and unchanged composition of the tablet, based on the active ingredient, the matrix forming agent and the optional components. All these pharmaceutical compositions exhibit a corresponding release behavior.
  • It is also surprising that, in the compositions according to the invention with a given amount of active ingredient, the quantity of matrix forming agent and the quantity of optional components can each vary over a relatively large range without affecting the therapeutic efficacy of at least 12 hours or with twice daily administration (providing that the above-mentioned limits on the quantity of active ingredient, matrix forming agent and further optional components are adhered to). Efficacy over at least 12 hours is assured, for example, with an active ingredient content of approx. 32.25% by weight (based on the weight of the total composition) in a composition of approx. 12.9% by weight HPMC having a viscosity of 100,000 mPa·s as matrix forming agent and a content of approx. 52.6% by weight of, for example, MCC as filler and also in a composition of approx. 25.8% by weight of the same HPMC and approx. 39.7% by weight MCC (or lactose monohydrate) with otherwise identical amounts of glidant, lubricant and flow regulators. The same applies to compositions according to the invention with a higher or lower active ingredient content within the specified limits.
  • It has also extremely surprisingly been found that, when the pharmaceutical formulations according to the invention with slow release of the active ingredient are administered to human volunteers, a biocompatibility which is the same as in formulations with immediate release of active ingredients is unexpectedly achieved despite the high first-pass effect for the active ingredient.
  • Compositions according to the invention which have a tmax value in the in vivo plasma concentration/time graph of between 2 and 10 hours, in particular between 3.5 and 6 hours and more particularly preferably between 4 and 5.5 hours after oral administration of the composition, i.e. compositions which yield peak plasma levels during said periods, are also preferred.
  • As active ingredient, the formulation according to the invention contains 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol as such and/or as a pharmaceutically acceptable salt in an amount typically of 2.5 to 800 mg, in particular 5 to 400 mg, more particularly preferably 10 to 250 mg (weight of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol as hydrochloride) per dose unit. The release behavior of the formulation according to the invention is not affected by the exact amount of the active ingredient provided that the above-mentioned limits are adhered to. Due to the different active strength of the two particularly preferred enantiomers (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, it is preferred if the stronger (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol exists in an amount of 2.5 to 80 mg, in particular 5 to 40 mg and more particularly preferably in an amount of 10 to 25 mg active ingredient (based on the hydrochloride) in the formulations according to the invention, while the (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol preferably is present in an amount of 25 to 800 mg, in particular 50 to 400 mg and more particularly preferably in an amount of 100 to 250 mg active ingredient (based on the hydrochloride) in the formulations according to the invention, more specifically on condition that the above-mentioned limits are adhered to.
  • Within the scope of this invention, the term “pharmaceutically acceptable salt” of the active ingredient refers to a salt of the active ingredient which is physiologically acceptable for pharmaceutical use, in particular when administered to mammals and/or humans. Pharmaceutically acceptable salts of this type may be formed, for example, with inorganic or organic acids.
  • The pharmaceutical formulations according to the invention can exist both as a simple tablet and as a coated tablet, for example as a film tablet or dragee. The tablets are typically round and biconvex, but oblong tablet shapes which allow the tablet to be divided are also possible. Granules, spheroids, pellets or microcapsules which are poured into sachets or capsules or may be compressed to disintegrating tablets are also possible within the scope of the invention.
  • One or more coating layers may be used for the coated tablets. Suitable coating materials include known hydroxypropylmethyl celluloses having a low viscosity of approx. 1 to 100 mPa·s and a low molecular weight of <10,000 (for example Pharmacoat 606 with a viscosity of 6 mPa·s in a 2% by weight aqueous solution at 20° C.), which only slightly influence the release profile of the pharmaceutical compositions according to the invention. Diffusion coatings known to persons skilled in the art and based, for example, on swellable but water-insoluble poly(meth)acrylates lead to modulation of the slow release of the active ingredients from pharmaceutical formulations according to the invention. The tablet core which contains the active ingredient, releases the active ingredient slowly and has an active ingredient content preferably between 0.5 and 85% by weight, particularly preferably between 3 and 70% by weight and more particularly preferably between 8 and 66% by weight. The tablet core can be sheathed with additional active ingredient which is released as an initial dose without retardation by various processes known to persons skilled in the art, for example dragee production, spraying from solutions or suspensions or by application of powder, but without this being absolutely essential for the desired slow release with a simultaneous rapid initial flow of the active ingredient for rapid pain relief on first administration of the pharmaceutical formulation according to the invention. Multilayered and shell-type tablets represent further embodiments, in which 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof is released slowly in one or more layers of the multilayer tablet with an active ingredient content preferably between 0.5 and 85% by weight, particularly preferably between 3 and 70% by weight, and more particularly preferably between 8 and 66% by weight, or in the core of the shell-type tablet with an active ingredient content preferably between 0.5 and 85% by weight, particularly preferably between 3 and 70% by weight, and more particularly preferably between 8 and 66% by weight by a pharmaceutically acceptable matrix forming agent, and the release of the active ingredient takes place without retardation in one or more layers of the multilayer tablet or the outer shell layer of the shell-type tablets. Multilayer and shell-type tablets can contain one or more coatings which are free from active ingredients.
  • Instead of a slow release matrix in the slow release pharmaceutical formulation, it is also possible to use a normal release matrix with a coating which retards release of the active ingredient. For example, the active ingredient can be contained in a conventional matrix of microcrystalline cellulose and optionally further pharmaceutical auxiliaries such as binders, fillers, glidants, lubricants and flow regulators, which are covered or coated with a material controlling the slow release of the active ingredient in an aqueous medium. Suitable coating agents include, for example, water-insoluble waxes and polymers such as polymethacrylates (Eudragit or the like) or water-insoluble celluloses, in particular ethyl cellulose. The coating material can optionally also contain water-soluble polymers such as polyvinyl pyrrolidone, water-soluble celluloses such as hydroxypropylmethyl cellulose or hydroxypropyl cellulose, other water-soluble agents such as Polysorbate 80 or hydrophilic pore-forming agents such as polyethylene glycol, lactose or mannitol.
  • As an alternative or a supplement to the possibilities of a slow release matrix in the delayed release pharmaceutical formulation or of a normal release matrix with a coating which retards the release of the active ingredient, an osmotically driven release system can also be used to achieve a slow release. With a release system of this type, preferably an oral system, at least one, preferably all, surface(s) of the release system, preferably those which are in contact or which may come into contact with the release medium, are semi-permeable, preferably provided with a semi-permeable coating, so the surfaces are permeable to the release medium but substantially, and preferably completely, impermeable to the active ingredient, whereby the surface and/or optionally the coating comprises at least one opening for releasing the active ingredient. The active ingredient 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof, preferably (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof and/or (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof or a mixture thereof can, but does not have to, be present in a matrix. This is preferably taken to mean a system in tablet form with a delivery opening, an osmotic pharmaceutical composition core, a semi-permeable membrane and a polymeric part which exerts pressure. A useful example of such a system is the OROS® system from ALZA Corporation, USA, details of which are available on the Alza Corporation internet site and/or in product literature of Alza Corporation. These include in particular the OROS® Push-Pull™ system, the OROS® Delayed Push-Pull™ system, the OROS® Multi-Layer Push-Pull™ system, the OROS® Push-Stick System and in certain cases the L-OROS™. Embodiments and examples of the actual production of osmotically driven release systems can be found in U.S. Pat. Nos. 4,765,989; 4,783,337 and 4,612,008, the complete disclosures of which are incorporated herein by reference.
  • The compositions according to the invention may be produced, for example, by the following general processes: weighed amounts of the components of the composition (active ingredient, matrix forming agent and optional components) successively introduced and then screened on a conventional screening machine, for example a Quadro Comil U10 screening machine using, for example, a conventional screen size of approx. 0.813 mm. The screened material is then mixed in a container mixer, for example a Bohle container mixer. Typical mixer operating conditions are: duration approx. 15 min±45 seconds at a speed of 20±1 rpm. The resulting powder mixture is subsequently compressed to a tablet on a tablet press, for example a Korsch EKO tablet press with a round die curved in the form of a dragee having a diameter of 10 mm. Alternatively, the powder mixture can be compacted and the compacts subsequently screened (Comill 3 mm friction macerating sieve and subsequent 1.2 mm round hole screen), the resulting granules then being compressed in the above-described manner with addition of lubricant (for example magnesium stearate) for example on an EKO tablet press with 10 mm round dies. Granulation can also be carried out by wet granulation using aqueous or organic solvents. Aqueous solvents with or without a suitable binder are preferred. The production process can readily be adapted to the respective requirements and the desired form of administration by procedures well known to persons skilled in the art.
  • The production of pharmaceutical formulations according to the invention is characterized by high repeatability of the release properties of the resulting compositions containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof. The release profile of pharmaceutical compositions according to the invention has proven to be stable for a storage time of at least one year under conventional storage conditions according to ICH Q1AR Stability Testing Guidelines.
  • With once or twice daily administration of a pharmaceutical formulation according to the invention by the patient, good therapeutic efficacy is reliably achieved in the case of continuously strong pain.
  • EXAMPLES
  • The following examples serve to illustrate the present invention and preferred embodiments, but do not restrict its scope.
  • Example 1
  • A batch of 1,000 matrix tablets was produced as described below having with the following composition per tablet:
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol 100 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90  80 mg
    SH 100,000 from Shinetsu,
    100,000 mPa · s
    Microcrystalline cellulose (Avicel PH 102 from FMC) 123 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg
  • All components were weighed in and screened on a Quadro Comil U10 screening machine using a screen size of 0.813 mm, mixed in a container mixer (Bohle LM 40) for 15 minutes±15 seconds at a speed of 20±1 rpm and pressed on a Korsch EK0 eccentric press to tablets curved in the manner of dragees with a diameter of 10 mm, a radius of curvature of 8 mm and an average tablet weight of 310 mg. The in vitro release was determined by the Ph. Eur. Paddle Method at 75 rpm in 900 ml pH 6.8 buffer according to Ph. Eur. at 37° C. and with detection using a UV spectrometer, and is reproduced in the following table:
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 18
     60 27
    120 41
    180 50
    240 59
    360 71
    480 80
    600 87
    720 93
  • Example 2
  • Using a process similar to that described in Example 1, 3,000 matrix tablets were produced having the following composition per tablet:
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol 200 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000  80 mg
    from Shinetsu, 100,000 mPa · s
    Microcrystalline cellulose (Avicel PH 102 from FMC)  23 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg
  • The in vitro release was determined as in Example 1.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 19
     60 30
    120 46
    180 58
    240 68
    360 84
    480 93
    720 99
  • Example 3
  • Using a process similar to that described in Example 1, a batch of 3,000 matrix tablets were produced having the following composition per tablet:
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol 100 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000 from  40 mg
    Shinetsu, 100,000 mPa · s
    Microcrystalline cellulose (Avicel PH 102 from FMC) 163 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg
  • The in vitro release was determined as in Example 1. In addition, the release was determined under otherwise identical conditions at stirring speeds of 50 and 100 rpm.
    Total amount of Total amount of Total amount of
    active ingredient active ingredient active ingredient
    Time released [%] released [%] released [%]
    (min) at 50 rpm at 75 rpm at 100 rpm
     0 0 0 0
     30 20 20 21
     60 35 33 35
    120 54 51 53
    180 67 63 66
    240 76 73 76
    360 89 87 89
    480 97 95 97
    600 100 100 100
  • Example 4
  • Using a process similar to that described in Example 1, a batch of 200 matrix tablets was produced having the following composition per tablet:
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol 100 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000 from  80 mg
    Shinetsu, 100,000 mPa · s
    Lactose monohydrate 230 (Meggle) 123 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg
  • The in vitro release was determined as in Example 1.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 16
     60 26
    120 39
    180 49
    240 57
    360 71
    480 81
    600 87
    720 92
  • Example 5
  • Matrix tablets with the following composition per tablet
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol 100 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000 from  40 mg
    Shinetsu, 100,000 mPa · s
    Cellactose 80 (Meggle) 163 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg

    were produced by a process similar to that described in Example 1 in a batch size of 100 tablets.
  • The in vitro release was determined as an Example 1.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 18
     60 31
    120 48
    180 61
    240 71
    360 84
    480 91
    600 95
    720 97
  • Example 6
  • Matrix tablets with the following composition per tablet
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol 100 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000 from  80 mg
    Shinetsu, 100,000 mPa · s
    Ludipress (BASF) 123 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg

    were produced by a process similar to that described in Example 1 in a batch size of 100 tablets.
  • The in vitro release was determined as in Example 1.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 17
     60 27
    120 40
    180 51
    240 59
    360 72
    480 82
    600 89
    720 93
  • Example 6
  • Matrix tablets with the following composition per tablet
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol  50 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000 from  40 mg
    Shinetsu, 100,000 mPa · s
    Microcrystalline cellulose (Avicel PH 102 from FMC) 163 mg
    Lactose 200 (Meggle)  50 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg

    were produced by a process similar to that described in Example 1 in a batch size of 200 tablets.
  • The in vitro release was determined as in Example 1.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 18
     60 31
    120 49
    180 61
    240 70
    360 82
    480 90
    600 94
    720 96
  • Example 8
  • Matrix tablets with the following composition per tablet
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol  100 mg
    hydrochloride
    Cellactose (Meggle) 72.5 mg
    Hydroxyethyl cellulose (Natrosol 250 HX from Herkules) 12.5 mg
    Cutina HR (Henkel)  130 mg
    Talcum   3 mg
    Magnesium stearate   2 mg
    Total amount  320 mg

    were produced as follows in a batch size of 200 tablets. The active ingredient, Cellactose, Natrosol and Cutina were mixed then heated to 80° C. in a drying oven and granulated in a Kenwood Chef kitchen mixer. The cooled granules were screened through a 1 mm screen. After blending with magnesium stearate and talcum, the granules were pressed on a EK0 eccentric press (Korsch) to 6×15 mm size oblong tablets with a breaking notch.
  • The in vitro release was determined as in Example 1.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 28
     60 39
    120 56
    180 68
    240 80
    360 97
    390 99
  • Example 9
  • Matrix tablets with the following composition per tablet
    (+)-(1S,2S)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol  10 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000 from  80 mg
    Shinetsu, 100,000 mPa · s
    Microcrystalline cellulose (Avicel PH 102 from FMC) 213 mg
    Lactose 200 (Meggle)  50 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 310 mg

    were produced by a process similar to that described in Example 1 in a batch size of 100 tablets.
  • The in vitro release was determined as in Example 1.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 15
     60 24
    120 36
    180 44
    240 51
    360 61
    480 69
    600 75
    720 79
  • Example 10
  • Matrix tablets with the following composition per tablet:
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol 100 mg
    hydrochloride
    Hydroxypropylmethyl cellulose (Metolose 90 SH 100,000 from  80 mg
    Shinetsu, 100,000 mPa · s
    Microcrystalline cellulose (Avicel PH 102 from FMC)  63 mg
    Highly dispersed silicon dioxide  4 mg
    Magnesium stearate  3 mg
    Total amount 250 mg

    were produced by a process similar to that described in Example 1 in a batch size of 100 tablets.
  • The in vitro release was determined under the following conditions:
    • (A) application of the Ph. Eur. Paddle Method at 75 rpm in 900 ml pH 7.2 buffer to USP 22 at 37° C. and with detection using a UV spectrometer;
  • (B) application of the Ph. Eur. Paddle Method at 75 rpm, a pH of 1.2 being adjusted from 0 to 30 min, a pH of 2.3 from 30 to 120 min, a pH of 6.5 from 120 to 180 min and a pH of 7.2 for the remaining test period. The table shows the results for both experimental conditions:
    Total amount of active Total amount of active
    ingredient released [%} ingredient released [%}
    Time (min) under condition (A) under condition (B)
     0 0 0
     30 19 20
     60 29 30
    120 43 44
    180 54 55
    240 63 65
    360 78 80
    480 87 90
    600 94 97
    720 98 100

    The experiment shows that the release behavior of the formulations according to the invention is independent of the pH of the release medium.
  • Example 11
  • Pellets were produced as described below having the following composition:
    (−)-(1R,2R)3-(3-dimethylamino-1-ethyl-2-methyl-propyl)   100 mg
    phenol hydrochloride
    Low-substituted hydroxypropyl cellulose (L-HPC LH 31 from   75 mg
    Shinetsu)
    Aquacoat (aqueous ethyl cellulose dispersion from FMC)   20 mg
    (calculated as dry substance)
    Microcrystalline cellulose (Avicel PH 101 from FMC)   75 mg
    Dibutyl sebacate (DBS)    4 mg
    Tween 80  0.4 mg
    Total amount 274.4 mg

    The active ingredient, Avicel and L-HPC were mixed for 10 minutes in a planetary mixer (Kenwood K Mixer) and then granulated with water. The moist granules were extruded in a Nica extruder with a 0.8×0.8 mm matrix and then rounded for 10 min in the Nica spheronizer at 500 rpm (1 kg loading). The pellets were dried overnight in a drying oven at 50° C. and then classified into screen fractions.
  • Pellets measuring 0.6 to 1.0 mm (yields about 95%) were coated in the WSG (smooth GPCG1 with a Wurster insert) at incoming air temperatures of 60° C. (product temperature 40° C.) with an aqueous dispersion of Aquacoat and DBS (20%, calculated on Aquacoat solids content), so they had an increase in weight of 9.8% (based on the original weight). The dispersion was produced in accordance with the manufacturer's instructions (FMC), the DBS together with the Tween 80 being homogenized in a proportion of the water and then being added to the dilute Aquacoat dispersion. The final dispersion had a solids content of 20% by weight and was stirred for at least 3 hours. The coated pellets were dried in the WSG and tempered in the drying oven (2 hours at 60° C.). The release was tested as in Example 1, but by the basket method at 100 rpm.
    Total amount of
    active ingredient
    Time (min) released [%]
     0 0
     30 5
     60 15
    120 28
    180 43
    240 56
    360 73
    480 82
    600 87
    720 90

    Clinical Trial
  • In a monocentric, open, randomized individual dose four-way crossover trial, various forms of administration of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol hydrochloride (active ingredient) were administered to sixteen healthy male white subjects aged from 18 to 45 years, to determine pharmacokinetic data. Data was determined experimentally by HPLC analysis. The following were administered:
  • “Capsule 100 mg”: capsules with immediate release of the active ingredient and 100 mg of active ingredient
  • “Capsule 25 mg”: capsules with immediate release of the active ingredient and 25 mg of active ingredient
  • “Tablet 100 mg”: tablet according to Example 1 (100 mg of active ingredient)
  • “Tablet 200 mg”: tablet according to Example 2 (200 mg of active ingredient)
  • The capsules were white-opaque hard gelatine capsules of size 0 EL with a filling of 360 mg, which were made up as follows:
  • “Capsule 100 mg”: 100 mg (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol hydrochloride, 152 mg microcrystalline cellulose, 8 mg Aerosil, 20 mg magnesium stearate and 80 mg Primojel (sodium carboxymethyl starch type A from Avebe);
  • “Capsule 25 mg”: 25 mg (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol hydrochloride, 227 mg microcrystalline cellulose, 8 mg Aerosil, 20 mg magnesium stearate and 80 mg Primojel (sodium carboxymethyl starch type A from Avebe))
  • The essential pharmacokinetic data are shown in the following table and the characteristic of the experimentally determined average serum concentration in FIG. 1.
    “Capsule “Capsule “Tablet “Tablet
    Parameter 25 mg” 100 mg” 100 mg” 200 mg”
    AUC 69 ± 14 318 ± 66  300 ± 51  667 ± 141
    [ng · h/ml]
    Cmax 14 ± 4  64 ± 19 23 ± 5  51 ± 13
    [ng/ml]
    tmax [h] 1.2 ± 0.4 1.5 ± 0.9 4.6 ± 1.3 4.8 ± 1.1
    MRT* [h] 5.8 ± 0.7 5.9 ± 0.9 10.7 ± 1.5  10.3 ± 1.1 
    HVD** 3.5 ± 1.2 3.6 ± 1.1 12.4 ± 2.8  11.9 ± 2.3 

    *MRT = “Mean Residence Time”

    **HVD = “Half Value Duration”
  • On the one hand, a comparison of “Capsule 100 mg” and “Tablet 100 mg” immediately shows that the formulations according to the invention excellently fulfil the task of providing a pharmaceutical formulation containing a 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol with slow release of active ingredient. On the other hand, when “Tablet 100 mg” is compared with “Tablet 200 mg” there is also very advantageous dose proportionality in the release behavior.
  • However, this also shows that the two compositions according to the invention, “Tablet 100 mg” and “Tablet 200 mg” release the active ingredient in a discernible amount but more slowly at the beginning than the two formulations with immediate release; with the two retarded formulations, however, the plasma level is higher than 10 ng/ml after only one hour and still sufficiently high after 16 hours to ensure an analgesic action. Simulation studies for “Tablet 100 mg” also showed that, with repeated administration of the pharmaceutical composition at 12 hourly intervals, serum levels are achieved which do not fall below 20 ng/ml, so good analgesic efficacy is ensured by twice daily administration. This represents great progress for the treatment, in particular of chronic painful conditions, and allows a significant improvement in patient compliance.
  • The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention my occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents thereof.

Claims (26)

1. A slow-release pharmaceutical formulation containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof as active ingredient in a matrix, wherein the matrix contains 1 to 80% by weight of one or more pharmaceutically acceptable hydrophilic or hydrophobic polymers as matrix forming agents and has the following release rate in vitro, measured by the Ph. Eur. Paddle Method at 75 rpm in a buffer (to Ph. Eur.) at a pH of 6.8 at 37° C. and detected using a UV spectrometer:
3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours,
5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour,
10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours,
15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours,
30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours,
more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours,
more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and
more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.
2. A pharmaceutical composition according to claim 1, wherein the matrix forming agents comprise cellulose ethers, cellulose esters or a mixture thereof having a viscosity of 10,000 to 150,000 mPa·s in a 2% by weight solution at 20° C.
3. A pharmaceutical composition according to claim 1, wherein the matrix forming agents comprise cellulose ethers, cellulose esters or a mixture thereof having a viscosity of 50,000 to 150,000 mPa·s in a 2% by weight solution at 20° C.
4. A pharmaceutical composition according to claim 1, wherein the matrix forming agent comprises at least one substance selected from the group consisting of hydroxypropylmethyl celluloses (HPMC), hydroxyethyl celluloses, hydroxypropyl celluloses (HPC), methyl celluloses, ethyl celluloses and carboxymethyl celluloses.
5. A pharmaceutical composition according to claim 1, wherein the matrix forming agent comprises at least one substance selected from the group consisting of hydroxypropylmethyl celluloses, hydroxyethyl celluloses, hydroxypropyl celluloses and hydroxypropyl celluloses.
6. A pharmaceutical composition according to claim 1, wherein said composition contains from 0.5 to 85% by weight active ingredient and from 8 to 40% by weight matrix forming agents.
7. A pharmaceutical composition according to claim 1, wherein said composition comprises from 3 to 70% by weight active ingredient and from 10 to 35% by weight matrix forming agents.
8. A pharmaceutical composition according to claim 7, wherein said composition comprises from 8 to 66% by weight active ingredient and from 10 to 30% by weight matrix forming agents.
9. A pharmaceutical composition according to claim 1, wherein a peak plasma level of the active ingredient is obtained in vivo 2 to 10 hours after administration of the composition.
10. A pharmaceutical composition according to claim 9, wherein the peak plasma level of the active ingredient is obtained in vivo 3.5 to 6 hours after administration of the composition.
11. A pharmaceutical formulation according to claim 1, wherein the active ingredient comprises (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical formulation according to claim 1, wherein the active ingredient comprises (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof.
13. A tablet for twice daily oral administration of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, said tablet containing a pharmaceutical formulation according to claim 1.
14. A slow-release pharmaceutical formulation containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof as active ingredient in a matrix, wherein the matrix contains 1 to 80% by weight of one or more pharmaceutically acceptable hydrophilic or hydrophobic polymers as matrix forming agents and comprises cellulose ethers cellulose esters or a mixture thereof having a viscosity of 3,000 to 150,000 mPa·s in a 2% by weight aqueous solution at 20° C.
15. A pharmaceutical composition according to claim 14, wherein the matrix forming agents comprise cellulose ethers, cellulose esters or a mixture thereof having a viscosity of 10,000 to 150,000 mPa·s in a 2% by weight solution at 20° C.
16. A pharmaceutical composition according to claim 14, wherein the matrix forming agents comprise cellulose ethers, cellulose esters or a mixture thereof having a viscosity of 50,000 to 150,000 mPa·s in a 2% by weight solution at 20° C.
17. A pharmaceutical composition according to claim 14, wherein the matrix forming agent comprises at least one substance selected from the group consisting of hydroxypropylmethyl celluloses (HPMC), hydroxyethyl celluloses, hydroxypropyl celluloses (HPC), methyl celluloses, ethyl celluloses and carboxymethyl celluloses.
18. A pharmaceutical composition according to claim 14, wherein the matrix forming agent comprises at least one substance selected from the group consisting of hydroxypropylmethyl celluloses, hydroxyethyl celluloses, hydroxypropyl celluloses and hydroxypropyl celluloses.
19. A pharmaceutical composition according to claim 14, wherein said composition contains from 0.5 to 85% by weight active ingredient and from 8 to 40% by weight matrix forming agents.
20. A pharmaceutical composition according to claim 14, wherein said composition comprises from 3 to 70% by weight active ingredient and from 10 to 35% by weight matrix forming agents.
21. A pharmaceutical composition according to claim 20, wherein said composition comprises from 8 to 66% by weight active ingredient and from 10 to 30% by weight matrix forming agents.
22. A pharmaceutical composition according to claim 14, wherein a peak plasma level of the active ingredient is obtained in vivo 2 to 10 hours after administration of the composition.
23. A pharmaceutical composition according to claim 22, wherein the peak plasma level of the active ingredient is obtained in vivo 3.5 to 6 hours after administration of the composition.
24. A pharmaceutical formulation according to claim 14, wherein the active ingredient comprises (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof.
25. A pharmaceutical formulation according to claim 14, wherein the active ingredient comprises (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or a pharmaceutically acceptable salt thereof.
26. A tablet for twice daily oral administration of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, said tablet containing a pharmaceutical formulation according to claim 14.
US10/831,368 2001-10-24 2004-04-26 Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol Abandoned US20050058706A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE2001152469 DE10152469A1 (en) 2001-10-24 2001-10-24 Delayed release analgesic formulations, comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol in hydrophilic or hydrophobic polymer matrix
DE10152469.2 2001-10-24
DE2002148309 DE10248309A1 (en) 2002-10-16 2002-10-16 Delayed release analgesic formulations, comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol in hydrophilic or hydrophobic polymer matrix
DE10248309.4 2002-10-16
PCT/EP2002/011809 WO2003035053A1 (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/242,800 US20120034304A1 (en) 2001-10-24 2011-09-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
US13/868,635 US20130237608A1 (en) 2001-10-24 2013-04-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
US15/018,529 US20160151309A1 (en) 2001-10-24 2016-02-08 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US15/377,628 US20170087103A1 (en) 2001-10-24 2016-12-13 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US15/943,175 US20180221308A1 (en) 2001-10-24 2018-04-02 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011809 Continuation WO2003035053A1 (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/242,800 Continuation US20120034304A1 (en) 2001-10-24 2011-09-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol

Publications (1)

Publication Number Publication Date
US20050058706A1 true US20050058706A1 (en) 2005-03-17

Family

ID=26010444

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/831,368 Abandoned US20050058706A1 (en) 2001-10-24 2004-04-26 Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US13/242,800 Abandoned US20120034304A1 (en) 2001-10-24 2011-09-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
US13/868,635 Abandoned US20130237608A1 (en) 2001-10-24 2013-04-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
US15/018,529 Abandoned US20160151309A1 (en) 2001-10-24 2016-02-08 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US15/377,628 Abandoned US20170087103A1 (en) 2001-10-24 2016-12-13 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US15/943,175 Pending US20180221308A1 (en) 2001-10-24 2018-04-02 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

Family Applications After (5)

Application Number Title Priority Date Filing Date
US13/242,800 Abandoned US20120034304A1 (en) 2001-10-24 2011-09-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
US13/868,635 Abandoned US20130237608A1 (en) 2001-10-24 2013-04-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
US15/018,529 Abandoned US20160151309A1 (en) 2001-10-24 2016-02-08 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US15/377,628 Abandoned US20170087103A1 (en) 2001-10-24 2016-12-13 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US15/943,175 Pending US20180221308A1 (en) 2001-10-24 2018-04-02 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

Country Status (27)

Country Link
US (6) US20050058706A1 (en)
EP (1) EP1439829B1 (en)
JP (2) JP4758064B2 (en)
KR (1) KR100958045B1 (en)
CN (1) CN100402021C (en)
AR (1) AR036943A1 (en)
AT (1) AT303802T (en)
BR (1) BR0213653A (en)
CA (1) CA2464578C (en)
CO (1) CO5570662A2 (en)
DE (1) DE50204198D1 (en)
DK (1) DK1439829T3 (en)
EC (1) ECSP045102A (en)
ES (1) ES2248622T3 (en)
HK (1) HK1068539A1 (en)
HU (1) HU230161B1 (en)
IL (2) IL161587D0 (en)
MX (1) MXPA04003742A (en)
MY (1) MY127797A (en)
NO (2) NO331896B1 (en)
NZ (1) NZ532999A (en)
PE (1) PE05272003A1 (en)
PL (1) PL216535B1 (en)
PT (1) PT1439829E (en)
SI (1) SI1439829T1 (en)
WO (2) WO2003035054A1 (en)
ZA (1) ZA200403928B (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US20050236741A1 (en) * 2004-04-22 2005-10-27 Elisabeth Arkenau Process for the production of an abuse-proofed solid dosage form
US20060002859A1 (en) * 2004-07-01 2006-01-05 Elisabeth Arkenau Process for production of an abuse-proofed solid dosage form
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060039864A1 (en) * 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060188447A1 (en) * 2005-02-04 2006-08-24 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20060193914A1 (en) * 2005-02-04 2006-08-31 Judy Ashworth Crush resistant delayed-release dosage forms
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20070183979A1 (en) * 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20070183980A1 (en) * 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Dosage form that is safeguarded from abuse
US20070213405A1 (en) * 2004-06-28 2007-09-13 Gruenenthal Gmbh Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
US20080311049A1 (en) * 2003-08-06 2008-12-18 Grunenthal Gmbh Abuse-proof dosage form
US20090004267A1 (en) * 2007-03-07 2009-01-01 Gruenenthal Gmbh Dosage Form with Impeded Abuse
US20090012180A1 (en) * 2007-04-23 2009-01-08 Gruenenthal Gmbh Titration of Tapentadol
US20090099138A1 (en) * 2006-04-28 2009-04-16 Gruenenthal Gmbh Pharmaceutical combination
US20090202634A1 (en) * 2008-01-25 2009-08-13 Grunenthal Gmbh Pharmaceutical dosage form
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
US20110082214A1 (en) * 2008-05-09 2011-04-07 Gruenthal Gmbh Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US20110187017A1 (en) * 2010-02-03 2011-08-04 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US20110306674A1 (en) * 2010-06-15 2011-12-15 Gruenenthal Gmbh Pharmaceutical Combination
WO2012000666A1 (en) 2010-06-30 2012-01-05 Grünenthal GmbH Tapentadol for use in the treatment of irritable bowel syndrome
WO2011138037A3 (en) * 2010-05-05 2012-03-15 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
WO2012136351A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
WO2012136349A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for preventing chronification of pain
WO2012146383A1 (en) 2011-04-29 2012-11-01 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
RU2473337C2 (en) * 2007-04-23 2013-01-27 Грюненталь Гмбх Tapentadol for treatment caused by osteoarthrosis
WO2013017233A1 (en) * 2011-07-29 2013-02-07 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
AU2008328548B2 (en) * 2007-11-23 2014-05-15 Grunenthal Gmbh Tapentadol compositions
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9133142B2 (en) 2010-07-23 2015-09-15 Gruenenthal Gmbh Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9642801B2 (en) 2008-10-30 2017-05-09 Gruenenthal Gmbh And potent tapentadol dosage forms
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1839654B9 (en) 2002-11-22 2012-01-11 Grünenthal GmbH Use of (1R, 2R)-3-(3-dimenthyl amino-1-ethyl-2-methyl-propyl) phenol for treating inflammatory pain
AU2005259478B2 (en) * 2004-07-01 2010-07-15 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR101396166B1 (en) 2006-04-28 2014-05-27 그뤼넨탈 게엠베하 Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
CN101091725A (en) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 Chinese traditional medicine grains and preparation method
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
CN101939287B (en) * 2007-12-07 2014-10-22 格吕伦塔尔有限公司 (1r, 2r) -3- (3- Dimethylamino-1-ethyl-2-methylpropyl) - - -phenol thereof
BR112013022556A8 (en) 2011-03-04 2018-01-16 Gruenenthal Gmbh semisolid aqueous pharmaceutical composition containing tapentadol, their use and the use of tapentadol
BR112013022495A2 (en) 2011-03-04 2016-12-06 Grünenthal GmbH aqueous pharmaceutical formulation for oral administration of tapentadol
WO2012119728A1 (en) 2011-03-04 2012-09-13 Grünenthal GmbH Parenteral administration of tapentadol
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
TW201642843A (en) 2015-03-27 2016-12-16 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
US20180085328A1 (en) 2016-09-23 2018-03-29 Gruenenthal Gmbh Stable Formulation for Parenteral Administration of Tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4844909A (en) * 1986-10-31 1989-07-04 Euroceltique, S.A. Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt
US5741524A (en) * 1995-01-09 1998-04-21 Edward Mendell Co., Inc. Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5955104A (en) * 1996-07-25 1999-09-21 Asta Medica Ag Multiple unit oral pharmaceutical formulations
US6143322A (en) * 1993-07-01 2000-11-07 Purdue Pharma L.P. Method of treating humans with opioid formulations having extended controlled release
US6177102B1 (en) * 1998-08-13 2001-01-23 Andrx Pharmaceuticals, Inc. Once daily analgesic tablet
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6248737B1 (en) * 1994-07-23 2001-06-19 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
US6340475B2 (en) * 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6436441B1 (en) * 1992-09-18 2002-08-20 Yamanouchi Pharmaceutical Co., Ltd. Hydrogel-forming sustained-release preparation
US6689386B2 (en) * 1996-07-08 2004-02-10 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393B1 (en) * 1982-03-26 1985-10-22
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (en) 1994-12-28 1996-07-03 顺德市广容制药厂 Manufacture method of "Luotongding"pain-killing tablet
AU764453B2 (en) * 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4844909A (en) * 1986-10-31 1989-07-04 Euroceltique, S.A. Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US6436441B1 (en) * 1992-09-18 2002-08-20 Yamanouchi Pharmaceutical Co., Ltd. Hydrogel-forming sustained-release preparation
US6254887B1 (en) * 1993-05-10 2001-07-03 Euro-Celtique S.A. Controlled release tramadol
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US6143322A (en) * 1993-07-01 2000-11-07 Purdue Pharma L.P. Method of treating humans with opioid formulations having extended controlled release
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5672360A (en) * 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6248737B1 (en) * 1994-07-23 2001-06-19 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
US5741524A (en) * 1995-01-09 1998-04-21 Edward Mendell Co., Inc. Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
US6689386B2 (en) * 1996-07-08 2004-02-10 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US5955104A (en) * 1996-07-25 1999-09-21 Asta Medica Ag Multiple unit oral pharmaceutical formulations
US6340475B2 (en) * 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6177102B1 (en) * 1998-08-13 2001-01-23 Andrx Pharmaceuticals, Inc. Once daily analgesic tablet

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US8420056B2 (en) 2003-08-06 2013-04-16 Grunenthal Gmbh Abuse-proofed dosage form
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US20060193782A1 (en) * 2003-08-06 2006-08-31 Johannes Bartholomaus Abuse-proofed dosage form
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US20070183979A1 (en) * 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20070183980A1 (en) * 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Dosage form that is safeguarded from abuse
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US20080311049A1 (en) * 2003-08-06 2008-12-18 Grunenthal Gmbh Abuse-proof dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20080317854A1 (en) * 2004-04-22 2008-12-25 Grunenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20050236741A1 (en) * 2004-04-22 2005-10-27 Elisabeth Arkenau Process for the production of an abuse-proofed solid dosage form
US7994364B2 (en) 2004-06-28 2011-08-09 Gruenenthal Gmbh Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
US20100160447A1 (en) * 2004-06-28 2010-06-24 Gruenenthal Gmbh Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
US20070213405A1 (en) * 2004-06-28 2007-09-13 Gruenenthal Gmbh Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
US20060002859A1 (en) * 2004-07-01 2006-01-05 Elisabeth Arkenau Process for production of an abuse-proofed solid dosage form
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US8323889B2 (en) 2004-07-01 2012-12-04 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20080312264A1 (en) * 2004-07-01 2008-12-18 Grunenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20060039864A1 (en) * 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20060193914A1 (en) * 2005-02-04 2006-08-31 Judy Ashworth Crush resistant delayed-release dosage forms
US20100151028A1 (en) * 2005-02-04 2010-06-17 Grunenthal Gmbh Crush resistant delayed-release dosage forms
US20080311197A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20060188447A1 (en) * 2005-02-04 2006-08-24 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20080311187A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Crush resistan delayed-release dosage form
US20090099138A1 (en) * 2006-04-28 2009-04-16 Gruenenthal Gmbh Pharmaceutical combination
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US20090004267A1 (en) * 2007-03-07 2009-01-01 Gruenenthal Gmbh Dosage Form with Impeded Abuse
EP2422778A1 (en) 2007-04-23 2012-02-29 Grünenthal GmbH Titration of tapentadol
AU2008241013B2 (en) * 2007-04-23 2013-06-20 Grunenthal Gmbh Titration of tapentadol
US20090012180A1 (en) * 2007-04-23 2009-01-08 Gruenenthal Gmbh Titration of Tapentadol
RU2473337C2 (en) * 2007-04-23 2013-01-27 Грюненталь Гмбх Tapentadol for treatment caused by osteoarthrosis
EP2857013A1 (en) 2007-04-23 2015-04-08 Grünenthal GmbH Tapentadol for the treatment of pain in arthrosis
EP3143993A1 (en) 2007-04-23 2017-03-22 Grünenthal GmbH Titration of tapentadol
RU2472497C2 (en) * 2007-04-23 2013-01-20 Грюненталь Гмбх Tapentadol titration
AU2008328548B2 (en) * 2007-11-23 2014-05-15 Grunenthal Gmbh Tapentadol compositions
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20090202634A1 (en) * 2008-01-25 2009-08-13 Grunenthal Gmbh Pharmaceutical dosage form
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US20110082214A1 (en) * 2008-05-09 2011-04-07 Gruenthal Gmbh Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US10206890B2 (en) 2008-09-05 2019-02-19 Gruenenthal Gmbh Pharmaceutical combination
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
US9642801B2 (en) 2008-10-30 2017-05-09 Gruenenthal Gmbh And potent tapentadol dosage forms
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20110187017A1 (en) * 2010-02-03 2011-08-04 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US9884022B2 (en) 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2011138037A3 (en) * 2010-05-05 2012-03-15 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
US20130116333A1 (en) * 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
US20110306674A1 (en) * 2010-06-15 2011-12-15 Gruenenthal Gmbh Pharmaceutical Combination
WO2012000666A1 (en) 2010-06-30 2012-01-05 Grünenthal GmbH Tapentadol for use in the treatment of irritable bowel syndrome
US9133142B2 (en) 2010-07-23 2015-09-15 Gruenenthal Gmbh Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
WO2012136351A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
EP3449917A2 (en) 2011-04-05 2019-03-06 Grünenthal GmbH Tapentadol for preventing chronification of pain
WO2012136349A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for preventing chronification of pain
US9980927B2 (en) 2011-04-29 2018-05-29 Gruenenthal Gmbh Use of tapentadol for inhibiting and/or treating depression and anxiety
EP3272343A1 (en) 2011-04-29 2018-01-24 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
WO2012146383A1 (en) 2011-04-29 2012-11-01 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
US8895623B2 (en) 2011-07-29 2014-11-25 Gruenenthal Gmbh Intrathecal or epidural administration of 3-[(1S,25)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
WO2013017233A1 (en) * 2011-07-29 2013-02-07 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
EP3300726A1 (en) * 2011-07-29 2018-04-04 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
JP2014524924A (en) * 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3 - [(1s, 2s) -3- (dimethylamino) -1-ethyl-2-methylpropyl] phenol intrathecal or epidural administration
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction

Also Published As

Publication number Publication date
NO2012007I2 (en) 2013-01-02
EP1439829B1 (en) 2005-09-07
MXPA04003742A (en) 2004-07-23
JP4758064B2 (en) 2011-08-24
US20160151309A1 (en) 2016-06-02
PE05272003A1 (en) 2003-07-26
IL161587D0 (en) 2004-09-27
SI1439829T1 (en) 2006-02-28
HK1068539A1 (en) 2006-04-21
CO5570662A2 (en) 2005-10-31
DE50204198D1 (en) 2005-10-13
EP1439829A1 (en) 2004-07-28
NO20041924L (en) 2004-05-11
PL369756A1 (en) 2005-05-02
PL216535B1 (en) 2014-04-30
DK1439829T3 (en) 2005-10-10
ECSP045102A (en) 2004-06-28
US20130237608A1 (en) 2013-09-12
WO2003035053A1 (en) 2003-05-01
JP2005506367A (en) 2005-03-03
KR20040047964A (en) 2004-06-05
NO331896B1 (en) 2012-04-30
IL161587A (en) 2009-12-24
JP2010280697A (en) 2010-12-16
ES2248622T3 (en) 2006-03-16
BR0213653A (en) 2004-10-26
ZA200403928B (en) 2005-07-27
CN1607947A (en) 2005-04-20
HU230161B1 (en) 2015-09-28
CN100402021C (en) 2008-07-16
AR036943A1 (en) 2004-10-13
MY127797A (en) 2006-12-29
CA2464578C (en) 2011-10-11
US20120034304A1 (en) 2012-02-09
NO2012007I1 (en) 2012-05-21
US20180221308A1 (en) 2018-08-09
US20170087103A1 (en) 2017-03-30
WO2003035054A1 (en) 2003-05-01
NZ532999A (en) 2007-06-29
AT303802T (en) 2005-09-15
KR100958045B1 (en) 2010-05-17
HU0402104A2 (en) 2005-03-29
CA2464578A1 (en) 2003-05-01
PT1439829E (en) 2005-11-30

Similar Documents

Publication Publication Date Title
EP0516141B1 (en) Pharmaceutical controlled-release composition with bioadhesive properties
AU764866B2 (en) New sustained release oral formulations
EP0776660B1 (en) Long-lasting release nifedipine preparation
RU2311903C2 (en) Tamzulosin tablets
US6576260B2 (en) Sustained-release form of administration containing tramadol saccharinate
US7906141B2 (en) Sustained-release, oral pharmaceutical forms of formulation
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
EP0271193B1 (en) Controlled release hydromorphone composition
US20050158383A1 (en) Quetiapine formulations
US20060018957A1 (en) Pharmaceutical dosage forms including rasagiline
JP4969586B2 (en) Multiple unit type sustained release oral formulation and manufacturing method thereof
CA2131350C (en) Sustained release drug formulation containing a tramadol salt
AU2002314515B2 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
US6515010B1 (en) Carvedilol methanesulfonate
US8637512B2 (en) Formulations and method of treatment
US5902632A (en) Method of preparation of controlled release nifedipine formulations
US20060228415A1 (en) Modified release tablet of bupropion hydrochloride
US20020182256A1 (en) Novel oral dosage form for carvedilol
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects
CN100402021C (en) Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US20160015642A1 (en) Controlled dose drug delivery system
CN1625390A (en) Multi-stage oral drug controlled-release system
HU0201686A2 (en) Multilayered tablet for administration of a fixed combination of tramadol and diclofenac
US20140242063A1 (en) Pharmaceutical compositions
JP2001524950A (en) Pharmaceutical compositions for the controlled release of the active substance

Legal Events

Date Code Title Description
AS Assignment

Owner name: GRUENENTHAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARTHOLOMAEUS, JOHANNES;ZIEGLER, IRIS;REEL/FRAME:015763/0561

Effective date: 20040721

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION